The London-listed drugmaker, which reports its results in U.S. dollars, reported adjusted profit of $1.92 per share on sales of about $10.9 billion.
Sales of its COVID-19 vaccine dropped to $28 million in the first quarter, versus $1.14 billion over the same period last year, as the company lost ground to rival mRNA shots.Excluding sales of its COVID-19 products, sales rose 22% to $3.1 billion in emerging markets on a constant currency basis. Sales in China were hurt last year by lower drug prices, while the country's tough zero-COVID policy, which was abandoned in December, has kept some patients from being diagnosed and seeking care.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: